JTX-8064 + pimivalimab

JTX-8064 + pimivalimab is an investigational **combination therapy** being developed primarily for the treatment of advanced solid tumors, including platinum-resistant ovarian cancer. **JTX-8064** is a humanized IgG4 monoclonal antibody targeting the myeloid-specific receptor leukocyte immunoglobulin-like receptor B2 (LILRB2/ILT4), acting as an antagonist that blocks LILRB2 binding to its ligands and potentially reprograms immune-suppressive macrophages within the tumor microenvironment to an anti-tumor phenotype[1][3][5][7]. **Pimivalimab** (formerly JTX-4014) is a fully human monoclonal antibody that inhibits programmed cell death protein 1 (PD-1), antagonizing PD-1 to augment T lymphocyte effector function and promote anti-cancer immunity[2][4][6]. The combination aims to simultaneously alleviate two major mechanisms of tumor immune evasion (myeloid cell suppression and T cell checkpoint inhibition), and has demonstrated durable and deep partial responses in heavily pretreated patients with platinum-resistant ovarian cancer, as well as signals of efficacy in other tumor types[1][3][5][7]. The combination has been well tolerated, with grade 3 or higher adverse events reported in under 10% of patients[1][3].

Other names

JTX-8064 + pimivalimab